
    
      This is a multicentric prospective observational study to validate blood non-invasive
      biomarkers for NASH and fibrosis stage.

      150 subjects will be enrolled; 100 subjects with biopsy-proven NASH and 50 subjects with
      normal liver will be used as controls.
    
  